12:00 AM
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TH-302: Phase I/II started

Threshold began a 3-part, open-label, U.S. Phase I/II trial to evaluate IV TH-302 alone and in combination with Velcade bortezomib in up to 60 MM patients who received >=2 lines of therapy. In the first part, 6-patient cohorts will receive escalating doses of TH-302 given on days 1, 4, 8 and 11...

Read the full 248 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >